Idera Pharmaceuticals, Inc. (IDRA)
(Delayed Data from NSDQ)
$3.57 USD
+0.51 (16.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.57 USD
+0.51 (16.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Are Options Traders Betting on a Big Move in Idera Pharmaceuticals (IDRA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Idera Pharmaceuticals (IDRA) stock based on the movements in the options market lately.
Idera Pharmaceuticals (IDRA) in Focus: Stock Moves 9.4% Higher
by Zacks Equity Research
Idera Pharmaceuticals (IDRA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Idera Completes Recruitment in Late-Stage Melanoma Study
by Zacks Equity Research
Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.
Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.
Idera Pharmaceuticals (IDRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Idera (IDRA) delivered earnings and revenue surprises of 7.14% and 1348.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Idera Pharmaceuticals (IDRA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idera Pharmaceuticals, Inc. (IDRA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (IDRA).
Idera Pharmaceuticals (IDRA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Idera Pharmaceuticals (IDRA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idera Pharmaceuticals (IDRA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Idera (IDRA) delivered earnings and revenue surprises of 17.86% and -93.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Idera Pharmaceuticals (IDRA) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
vTv Therapeutics (VTVT) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Idera Pharmaceuticals (IDRA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Idera (IDRA) delivered earnings and revenue surprises of 26.25% and -9.44%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
by Zacks Equity Research
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Idera Stock Down, Study on Dermatomyositis Candidate Fails
by Zacks Equity Research
Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.
Options Traders Expect Huge Moves in Idera Pharmaceuticals (IDRA) Stock
by Zacks Equity Research
Investors in Idera Pharmaceuticals (IDRA) need to pay close attention to the stock based on moves in the options market lately.
BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall
by Zacks Equity Research
Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.
Is the Options Market Predicting a Spike in Idera (IDRA) Stock?
by Zacks Equity Research
Investors in Idera (IDRA) need to pay close attention to the stock based on moves in the options market lately.
Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%
by Zacks Equity Research
Idera Pharmaceuticals (IDRA) shares rose more than 14% in the last trading session, amid huge volumes.
Idera Pharmaceuticals (IDRA) Looks Good: Stock Up 13.3%
by Zacks Equity Research
Idera Pharmaceuticals, Inc. (IDRA) shares rose over 13% in the last trading session.